Individualizing Lifestyle Therapy for Patients with Obesity
Section snippets
The Role and Benefits of Pharmacotherapy in Obesity Management
Although lifestyle intervention alone often results in weight loss adequate to alleviate health symptoms in some patients, medications can help patients who are struggling to achieve weight-loss goals. Weight-loss medications, which should always be used as an add-on to a lifestyle intervention program, enhance the patient’s ability to adhere to a reduced- calorie meal plan and increase weight loss 49., 50., 51., 52., 53., 54.. The addition of medication to a lifestyle intervention provides
Strategies to Develop Individualized Pharmacotherapy Regimens
General prescribing principles apply to all weight-loss medications used to treat patients with obesity (Fig. 7). Medication should be considered when the patient who has a BMI of 27 to 29.9 kg/m2 and one obesity-related complication or when a patient has a BMI > 30 kg/m2. Medication use should be initiated when lifestyle therapy alone fails and the patient progressively gains weight or has no clinical improvement in weight-related complications (56). If a patient has weight gain following
Three Domains for Pharmacologic Individualization
When considering treatment for a patient with overweight or obesity, it is important to consider patient, biologic, and pharmacotherapeutic factors (Table 3). Understanding patient factors enables the physician to develop a weight-loss plan with a greater likelihood of success. Biologic factors affect the success of a weight-loss plan and need to be taken into account when setting realistic weight-loss goals. The weight- related complications being treated also need to be considered, as the
Summary and Conclusions
When creating a therapeutic plan to reduce weight and alleviate weight-related complications in patients with overweight or obesity, physicians must take into account the patient’s unique presentation, including concurrent disease, medical history, lifestyle preferences, psychological issues, and other patient-related factors, in order to individualize lifestyle therapy and pharmacotherapy that will enable the patient to achieve successful health outcomes. Effective patient-physician
Self-Assessment Test
Supplement from a live satellite symposium conducted in Orlando, Florida, on May 26, 2016, in conjunction with the AACE 25th Annual Scientific and Clinical Congress. To receive CME credit, please enter the self-assessment test answers and complete the activity evaluation. Credit is awarded to test scores > 70%. There are no fees to participate and receive credit. CME certificates will be mailed within 4 to 6 weeks of receipt of the self-assessment test and evaluation. Mail, email or fax the
REFERENCES (82)
- et al.
American Association of Clinical Endocrinologists’ Position Statement on obesity and obesity medicine
Endocr Pract.
(2012) - et al.
American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for comprehensive medical care of patients with obesity
Endocr Pract.
(2016) - et al.
The impact of physician weight discussion on weight loss in US adults
Obes Res Clin Pract.
(2014) - et al.
Ble- ich SN
Perceived judgment about weight can negatively influence weight loss: a cross-sectional study of overweight and obese patients. Prev Med.
(2014) - et al.
Overweight, obesity, and cancer risk
Lancet Oncol.
(2002) - et al.
Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis
Am J Clin Nutr.
(1992) - et al.
Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial
Obesity (Silver Spring).
(2013) - et al.
Obesity and weight loss in the treatment and prevention of osteoarthritis
PM R.
(2012) - et al.
Maintenance and relapse after weight loss in women: behavioral aspects
Am J Clin Nutr.
(1990) - et al.
Persons successful at long-term weight loss and maintenance continue to consume a low-energy, low-fat diet
J Am Diet Assoc.
(1998)